The biotech’s efforts to bring its vaccines to the country mean navigating political pushback in the U.S. and the risk of ...

In a report released on January 7, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

Norovirus, often erroneously called the "stomach flu," sickens an estimated 21 million Americans and 685 million people ...

The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023 ...

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

Despite millions of cases of norovirus in the U.S. each year—and a current surge in outbreaks—there is still no vaccine for ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

The potential payout relates to an earlier deal over tax evasion by U.S. clients of Credit Suisse, the rival Swiss bank that UBS acquired in 2023. Seven & i reported a drop in quarterly net profit but ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

The NHS has warned of a ‘quad-demic’ as respiratory virus cases rise, so what’s the best way to kill the ‘stomach bug’ virus?